GlassScriptPhysician profile
Middey Damian
NPI 1013938422
$23,315.91
in general payments reported to CMS, 2019-2025
37 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,098 · 2020: $8,392 · 2021: $6,130 · 2022: $1,204 · 2023: $1,001 · 2024: $1,103 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,468 · Education: $23.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,467.95 |
| Education | $23.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13,719.12 | 2019-2025 | Lupron Depot |
| Dexcom, INC. | $3,375.20 | 2019-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novo Nordisk INC | $1,046.44 | 2019-2025 | Sogroya, Wegovy, Norditropin |
| Ascendis Pharma Endocrinology INC | $830.96 | 2022-2025 | Skytrofa |
| Insulet Corporation | $561.30 | 2019-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $483.36 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Tolmar Pharmaceuticals, INC. | $360.34 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $330.26 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $244.70 | 2020-2023 | Gvoke Hypopen |
| Tolmar, INC. | $219.33 | 2023-2025 | Fensolvi |
| Lilly USA, LLC | $201.52 | 2019-2023 | Baqsimi |
| Abbott Laboratories | $171.00 | 2022-2025 | Freestyle Libre 3 |
| Zealand Pharma US, INC. | $152.96 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $149.84 | 2024-2025 | |
| Medtronic Minimed, INC. | $148.24 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $132.56 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Endo Pharmaceuticals INC. | $115.03 | 2020-2023 | Supprelin |
| Sandoz INC. | $108.35 | 2021-2025 | Omnitrope |
| Amphastar Pharmaceuticals, INC. | $92.34 | 2024-2025 | |
| Ibsa Pharma INC. | $91.51 | 2019-2023 | Tirosint, Licart |
| Lifescan, INC. | $88.40 | 2021-2023 | |
| Arbor Pharmaceuticals, INC. | $86.87 | 2019-2022 | |
| Pfizer INC. | $84.13 | 2023-2025 | |
| Ultragenyx Pharmaceutical INC. | $74.35 | 2022-2024 | Crysvita, Crysvita |
| Ferring Pharmaceuticals INC. | $71.63 | 2019-2020 | |
| Biomarin Pharmaceutical INC. | $55.19 | 2020-2022 | |
| Medtronic, INC. | $46.36 | 2021-2025 | Minimed 780g |
| Endo USA, INC. | $44.42 | 2025 | Supprelin |
| Vistapharm, INC. | $42.11 | 2021 | |
| Mannkind Corporation | $33.23 | 2019-2020 | |
| Rhythm Pharmaceuticals, INC. | $32.56 | 2025 | Imcivree |
| Azurity Pharmaceuticals, INC. | $27.40 | 2025 | Triptodur |
| Kyowa Kirin, INC. | $23.85 | 2023 | |
| Companion Medical, INC. | $23.48 | 2020 | |
| Sequel Med Tech, LLC | $19.05 | 2025 | Twiist |
| Amneal Pharmaceuticals LLC | $14.73 | 2022 | |
| Eton Pharmaceuticals, INC. | $13.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Middey Damian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.